Ionis Pharmaceuticals Inc IONS

US Biotechnology

$51.77 ▼ -2.83% ($-1.51)

⬇️ Below Yest. Low

Open $53.33

Prev Close $53.28

Day Range $51.28 – $53.33

52W Range $40.03 – $86.74

Market Cap $8.60B

Beta 0.38

EPS (TTM) $-2.10

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1991-05-17
Shares Out.	166,180,000
Website	ionis.com/ ↗
Phone	17609319200
Employees	1,402
Revenue	$267.9M
Gross Profit	$265.2M
Net Income	-$114.6M
Free Cash Flow	-$560.8M
Total Assets	$2.99B
Total Liabilities	$2.55B
Equity	$439.7M

About Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

Ionis Pharmaceuticals Inc is a publicly traded company under the ticker symbol IONS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.